Business
Ocumetics Announces Issuance of Shares
(TheNewswire) Calgary, Alberta – TheNewswire - June 2, 2023 - Ocumetics ...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Announces Issuance of Shares\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta\n \n \n –\n \n \n TheNewswire -\n \n \n June 2, 2023 - Ocumetics Technology Corp.\n \n \n (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) (the “\n \n \n Corporation\n \n \n ” or\n“\n \n \n Ocumetics\n \n \n ”) announces that it has issued 882,353 Common Shares to\nDr. Mark Lee and 835,294 Common Shares to Roger Jewett.  The proposed\nissuance of the shares was announced in the Corporation’s press\nrelease dated April 24, 2023.  The TSX Venture Exchange approved the\nissuance of the shares.\n \n \n \n \n Related Party Transactions\n \n \n \n \n Mark Lee is the President and CEO of the Corporation\nand Roger Jewett is the Chief Financial Officer of the Corporation.\n The issuance of shares to them therefore constitute “Related Party\nTransactions” under Multilateral Instrument 61-101 – Protection of\nMinority Security Holders in Special Transactions (“MI 61-101”).\n The Corporation relied upon the exemptions from the minority\nshareholder approval and valuation requirements set out in Sections\n5.7(1)(a) and 5.5(a), respectively, of MI 61-101.  The share\nissuances were unanimously approved by the directors of the\nCorporation by resolution.\n \n \n \n \n About Ocumetics\n \n \n \n \n Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)\n(FRA: 2QBO) is a Canadian research and development company that\nspecializes in adaptive intraocular lens designs. Ocumetics is in the\npreclinical study stage of a game-changing technology for the\nophthalmic industry.  Ocumetics has developed an expandable\nintraocular lens that fits within the capsular bag following\nextracapsular cataract extraction.  It is designed to allow the eyes\nnatural muscle activity to shift focus from distance to near,\npotentially to eliminate the need for corrective lenses.\n \n \n \n \n FOR FURTHER INFORMATION, PLEASE\nCONTACT:\n \n \n \n \n Dayton Marks, Director\n \n \n \n \n (778) 347-2500\n \n \n \n \n Neither the TSX\nVenture Exchange nor its Regulation Services Provider (as that term is\ndefined in the policies of the TSX Venture Exchange) accepts\nresponsibility for the adequacy or accuracy of this releas...